Barring an appeals court reversal, Amgen Inc. may be able to keep biosimilars to its top-selling drug Enbrel (etancercept) off the market for another decade now that a district court has upheld the validity of patents covering the compound's active ingredient and method of manufacture.
Three years after Sandoz Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?